Synthetic cannabinoid use among patients in residential substance use disorder treatment: Prevalence, motives, and correlates

Drug and Alcohol Dependence

Volumn 143, Issue 1, 2014, Pages 268-271

  Bonar, Erin E ^a   Ashrafioun, Lisham ^b,c   Ilgen, Mark A ^a,d  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b BOWLING GREEN STATE UNIVERSITY   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^d VA Serious Mental Illness Treatment Resource and Evaluation Center (SMITREC)   (United States)

Author keywords

Motivations; Substance use disorder treatment; Synthetic cannabinoids

Indexed keywords

CANNABINOID;

ADULT; AGE; ARTICLE; CANNABIS SMOKING; CANNABIS USE; CAUCASIAN; CORRELATION ANALYSIS; DEMOGRAPHY; DEPRESSION; DISTRESS SYNDROME; DRUG SCREENING; FEMALE; HUMAN; LEISURE; MAJOR CLINICAL STUDY; MALE; MOTIVATION; PREVALENCE; SELF REPORT; SUBSTANCE ABUSE; ALCOHOLISM; CROSS-SECTIONAL STUDY; DRUG DEPENDENCE TREATMENT; HOSPITAL PATIENT; INFORMATION PROCESSING; MARIJUANA ABUSE; MENTAL DISORDERS; MIDDLE AGED; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

ADULT; ALCOHOLISM; CANNABINOIDS; CROSS-SECTIONAL STUDIES; DATA COLLECTION; FEMALE; HUMANS; INPATIENTS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; MENTAL DISORDERS; MIDDLE AGED; MIDWESTERN UNITED STATES; MOTIVATION; PREVALENCE; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS;

EID: 84922407074     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.07.009     Document Type: Article

References (22)

1. Barratt M.J., Cakic V., Lenton S. Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev. 2013, 32:141-146.
2. Beck A.T., Wright F.D., Newman C.F., Liese B.S. Cognitive Therapy of Substance Abuse 1993, Guilford Press, New York.
3. Camp N.E. Synthetic cannabinoids. J. Emerg. Nurs. 2011, 37:292-293.
4. Centers for Disease Control and Prevention, 2013a. Acute Kidney Injury Associated with Synthetic Cannabinoid Use-Multiple States, 2012. MMWR, pp. 93-98.
5. Centers for Disease Control and Prevention, 2013b. Notes from the Field: Severe Illness Associated with Reported Use of Synthetic Marijuana-Colorado, August-September 2013. MMWR 62, 1016-1017.
6. Department of Justice, D.E.A., 2013. Schedules of Controlled Substances: Temporary Placement of Three Synthetic Cannabinoids into Schedule I. Federal Register 78, pp. 28735-28739.
7. Derogatis L.R., Melisaratos N. The brief symptom inventory: an introductory report. Psychol. Med. 1983, 13:595-605.
8. Derogatis L.R., Spencer M.S. The Brief Symptom Inventory (Bsi): Administration, Scoring, and Procedures Manual-1 1982, Johns Hopkins University School of Medicine, Clinical Psychometrics Research Unit, Baltimore.
9. Fantegrossi W.E., Moran J.H., Radominska-Pandya A., Prather P.L. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Delta-THC: mechanism underlying greater toxicity?. Life Sci. 2014, 97:45-54.
10. Forrester M.B., Kleinschmidt K., Schwarz E., Young A. Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum. Exp. Toxicol. 2012, 31:1006-1011.
11. Hu X., Primack B.A., Barnett T.E., Cook R.L. College students and use of K2: an emerging drug of abuse in young persons. Subst. Abuse Treat. Prev. Policy 2011, 6:16.
12. Hudson S., Ramsey J. The emergence and analysis of synthetic cannabinoids. Drug Test. Anal. 2011, 3:466-478.
13. Johnston L.D., Bachman J.G., O'Malley P.M., Schulenberg J.E. Monitoring the future: a continuing study of american youth (12th-grade survey), 2010. Core Data Codebook 2010, Inter-University Consortium For Political And Social Research, Ann Arbor.
14. Johnston L.D., O'Malley P.M., Miech R.A., Schulenberg J.E. Monitoring the future national results on drug use: 1975-2013. Overview, Key Findings on Adolescent Drug Use 2014, Institute for Social Research, The University of Michigan, Ann Arbor.
15. McLaren J.A., Silins E., Hutchinson D., Mattick R.P., Hall W. Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies. Int. J. Drug Policy 2010, 21:10-19.
16. McLellan A.T., Luborsky L., Woody G.E., O'Brien C.P. An improved diagnostic evaluation instrument for substance abuse patients. Addict. Severity Index. J. Nerv. Ment. Dis. 1980, 168:26-33.
17. Seely K.A., Lapoint J., Moran J.H., Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 39:234-243.
18. Vandrey R., Dunn K.E., Fry J.A., Girling E.R. A survey study to characterize use of spice products (synthetic cannabinoids). Drug Alcohol Depend. 2012, 120:238-241.
19. Vardakou I., Pistos C., Spiliopoulou C. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol. Lett. 2010, 197:157-162.
20. Wells D.L., Ott C.A. The "new" marijuana. Ann. Pharmacother. 2011, 45:414-417.
21. Winstock A.R., Barratt M.J. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend. 2013, 131:106-111.
22. Wood K.E. Exposure to bath salts and synthetic tetrahydrocannabinol from 2009 to 2012 in the United States. J. Pediatr. 2013, 163:213-216.